Intercept Pharma
Edit

Intercept Pharma

https://www.interceptpharma.com/
Last activity: 05.03.2024
Categories: BioTechCorporateDevelopmentInformationLivingMedtechWebsite
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on Twitter at: @InterceptPharma.
Followers
2.59K
Followers
47.77K
Website visits
7.2K /mo.
Mentions
58
Location: United States, New York
Employees: 501-1000
Total raised: $30M
Founded date: 2002

Investors 4

Funding Rounds 1

DateSeriesAmountInvestors
10.08.2012Series C$30M-

Mentions in press and media 58

DateTitleDescriptionSource
05.03.2024Elafibranor for Primary biliary cholangitis (PBC) in 7MM: Ma...-globenewsw...
26.09.2023Intercept, once a biotech trailblazer, sells itself for less...Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hot...statnews.c...
23.06.2023Intercept Announces Restructuring to Strengthen Focus on Rar...Measures reinforce Company’s ability to drive growth in PBC business and continue developing innovat...einpresswi...
28.04.2023Current NASH treatment hurdles highlighted, new drugs hailed...Michael Betel, President and Founder of the Fatty Liver Alliance testifies at ICER. Fatty Liver Alli...einpresswi...
11.11.2022Komodo Health & Intercept Partner to Study Rare Liver Di...What You Should Know: Intercept initially developed a traditional prospective trial to evaluate pati...hitconsult...
09.11.2022TES Pharma Congratulates Intercept Pharmaceuticals on their ...INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept ...en.prnasia...
05.05.2022Sequoia, Andreessen Horowitz, a Saudi prince, and other inve...This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ...fortune.co...
04.11.2021Corporate Presentation – November 2021Intercept Pharmaceuticals November 2021 Debbie, Living with PBC Cautionary Note Regarding Forward-Lo...marketscre...
03.11.2021Q3 2021 Earnings Call PresentationIntercept Pharmaceuticals 2021 Third Quarter Financial and Corporate Update November 3, 2021 Caution...marketscre...
03.11.2021Intercept Pharmaceuticals Reports Third Quarter 2021 Financi...Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update ...marketscre...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In